Q-omics provides the consensus-scored RPS15AP39 profile across patient tissues and cancer cell-line models. RPS15AP39 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RPS15AP39 is differentially expressed in 4, with the highest sampling consensus in ESCA. Additionally, RPS15AP39 RNA expression shows 11,997 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, ESCA, and GBM as cancer lineages where RPS15AP39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS15AP39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS15AP39 survival associations across molecular data types. RPS15AP39 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS15AP39 RNA expression–survival associations across cancer types. High RPS15AP39 expression shows unfavorable associations in COAD, UVM and PCPG, but favorable associations in CESC, KIRP and DLBC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify COAD as the clearest survival context for RPS15AP39 RNA expression.
This table summarizes RPS15AP39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS15AP39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS15AP39 shows lower tumor expression in LIHC and higher tumor expression in ESCA, STAD and COAD. The ESCA box plot shows higher RPS15AP39 RNA expression in tumor versus normal tissue (log2 FC = +1.505, t-test p = .047).
This table shows molecular features associated with RPS15AP39 in patient tissues and cancer cell lines. In patient samples, RPS15AP39 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
